English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, November 13, 2015
Carmeseal-MD(TM) Protects Skeletal Limb Muscle, the Third Major Target Muscle of Therapeutic Relevance in Duchenne Muscular Dystrophy (DMD)
Thursday, June 18, 2015
Phrixus Pharmaceuticals Receives Services From National Institutes of Health, NHLBI SMARTT Program to Produce Carmeseal-MD(TM) for Clinical Trial to Treat Duchenne Muscular Dystrophy
Wednesday, December 3, 2014
Phrixus Pharmaceuticals Announces European Access Program for Carmeseal-MD(TM) (P-188 NF) for Patients With Duchenne Muscular Dystrophy

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575